ANIK
Anika Therapeutics Inc.

636
Mkt Cap
$133.11M
Volume
161,494.00
52W High
$18.37
52W Low
$7.87
PE Ratio
-4.05
ANIK Fundamentals
Price
$9.63
Prev Close
$9.23
Open
$9.24
50D MA
$9.52
Beta
0.93
Avg. Volume
167,148.55
EPS (Annual)
-$3.83
P/B
0.91
Rev/Employee
$416,343.75
Loading...
Loading...
News
all
press releases
Anika Therapeutics Inc. $ANIK Shares Acquired by Capital Management Corp VA
Capital Management Corp VA grew its holdings in Anika Therapeutics Inc. (NASDAQ:ANIK - Free Report) by 34.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Anika Therapeutics (NASDAQ:ANIK) Share Price Passes Above 200-Day Moving Average - Time to Sell?
Anika Therapeutics (NASDAQ:ANIK) Stock Crosses Above 200-Day Moving Average - Time to Sell...
MarketBeat·17d ago
News Placeholder
ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP
The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Anika Therapeutics, Inc. (Anika or the Company) (NASDAQ:ANIK) investors concerning the Companys and/or members of...
Business Wire·1mo ago
News Placeholder
Acadian Asset Management LLC Boosts Position in Anika Therapeutics Inc. $ANIK
Acadian Asset Management LLC lifted its position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK - Free Report) by 6.7% in the second quarter, according to its most recent filing with the...
MarketBeat·3mo ago
News Placeholder
Anika Therapeutics (NASDAQ:ANIK) Upgraded at Wall Street Zen
Wall Street Zen upgraded Anika Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday...
MarketBeat·3mo ago
News Placeholder
Barrington Research Forecasts Strong Price Appreciation for Anika Therapeutics (NASDAQ:ANIK) Stock
Barrington Research increased their price target on shares of Anika Therapeutics from $15.00 to $16.00 and gave the company an "outperform" rating in a research note on Thursday...
MarketBeat·3mo ago
News Placeholder
Anika Therapeutics (NASDAQ:ANIK) Releases Quarterly Earnings Results, Misses Estimates By $0.19 EPS
Anika Therapeutics (NASDAQ:ANIK - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the...
MarketBeat·3mo ago
News Placeholder
Anika Therapeutics (ANIK) Q3 Earnings and Revenues Top Estimates
Anika (ANIK) delivered earnings and revenue surprises of +100.00% and +0.06%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains?
Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·5mo ago
News Placeholder
Wall Street Analysts See a 98.59% Upside in Anika (ANIK): Can the Stock Really Move This High?
The consensus price target hints at a 98.6% upside potential for Anika (ANIK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·5mo ago
<
1
2
...
>

Latest ANIK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.